India's chronic disease burden helped fuel Covid-19's brutal waves

For years India has faced an escalating non-communicable disease crisis as its middle-class expands and leads a more sedentary and affluent lifestyle

coronavirus, covid
Coronavirus test. Photo: PTI
Chris Kay | Bloomberg
3 min read Last Updated : Aug 14 2021 | 9:00 AM IST
High levels of chronic disease in India, such as diabetes and hypertension, helped stoke the brutal coronavirus waves that hit world’s second-most populous nation during the pandemic, researchers said.

The findings from one of the few large-scale studies of Covid-19 in India showed patients from the southern district of Madurai had a higher risk of dying than those in China, Europe, South Korea and the U.S., even though 63% of those tested were asymptomatic. Chronic health conditions in the community may have played a role, according to the report published in The Lancet.

For years India has faced an escalating non-communicable disease crisis as its middle-class expands and leads a more sedentary and affluent lifestyle. That makes them susceptible to ailments such as diabetes and heart disease that account for almost two-thirds of all deaths in the country. Those existing conditions may have allowed the coronavirus to do more damage, boosting cases and fatalities and potentially fueling the near collapse of India’s health system.

The death rate was 5.7% among Covid-19 patients with at least one existing health condition, compared to 0.7% in those who were otherwise healthy, the researchers found. The data came from more than 400,000 people who underwent coronavirus testing known as RT-PCR in Madurai from May 20 to Oct. 31, 2020, during India’s first wave.

“The findings that hypertension and diabetes actually predict acquisition of Covid itself, or at least being tested positive on an RT-PCR test, in itself is a significant finding,” Ramanan Laxminarayan, the study’s lead author and founder of the Center for Disease Dynamics, Economics & Policy, said in an interview. “Let’s just say India had half the diabetes and hypertension that we have, we probably would have seen a far smaller impact of the second wave.”

Managing health conditions that are common in the population should be at the top of the list for any government response to curbing the pathogen’s toll, he said.

Mass Underreporting

The researchers also highlighted what appears to be a mass underreporting of Covid cases and deaths in India after assessing the ratio between infections and fatalities, and the number of people in Madurai who were already producing infection-fighting antibodies between Oct. 19 and Nov. 5 last year. The results showed that testing found only 1.4% of infections, and just 11% of the expected number of deaths were detected.

Some scientists have estimated that as many as 5 million people may have died after India’s hospitals were overwhelmed during the second wave that peaked mid-May, a fraction of the official total tally of about 430,000 during the entire pandemic. The death toll is lower than what would have been expected given the number of known infections, the researchers said.

Researchers from the state government of Tamil Nadu, the University of California, Berkeley, Princeton University and the Johns Hopkins Bloomberg School of Public Health also contributed to the study.

It comes as India prepares for an expected third Covid wave that some experts forecast will be smaller than the second and could peak in October -- blunted in part by a growing wall of vaccinations and naturally acquired antibodies from past outbreaks. A national survey in July found that two-thirds of Indians above the age of six had been exposed to the coronavirus.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusDelta variant of coronavirusCoronavirus Vaccinechronic diseases

Next Story